Aspect Biosystems is a privately held biotechnology company combining the power of microfluidics and 3D bioprinting to fuel medical research and the development of bioprinted therapeutics. By adopting Aspect’s microfluidic 3D bioprinting platform and collaborating within Aspect’s network, researchers worldwide are accelerating the development and commercialization of 3D bioprinted tissues. In addition, Aspect is advancing its internal regenerative medicine programs focused on metabolic diseases and musculoskeletal injuries and disorders and partnering with key industry players to bring bioprinted therapeutics to the clinic.
Location: Canada, British Columbia, Vancouver
Employees: 51-200
Total raised: $142M
Founded date: 2013
Investors 7
| Date | Name | Website |
| - | Unreasonab... | unreasonab... |
| - | Endure Cap... | endurecap.... |
| 11.01.2022 | Civilizati... | civilizati... |
| - | Radical Ve... | radical.vc |
| - | Rhino Vent... | rhinovc.co... |
| - | E-Fund | e-fund.ca |
| - | New Ventur... | newventure... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 11.01.2025 | Series B | $115M | - |
| 16.01.2020 | Series A | $26M | - |
| 06.05.2018 | - | $1M | - |
Mentions in press and media 24
| Date | Title | Description |
| 27.03.2026 | Cellbricks Accelerates Organ Printing Vision with €10M Funding | Cellbricks Therapeutics secured €10M. This capital propels their biofabricated human tissue implants. The Berlin-Boston biotech firm revolutionizes regenerative medicine. Their proprietary light-based bioprinting platform creates vasculariz... |
| 25.03.2026 | Building the path to 3D-printed organs, Cellbricks raises €10M for biofabricated tissue implants | Berlin-founded biotech startup Cellbricks Therapeutics has raised €10 million to advance its goal of 3D-printed organs, beginning with biofabricated human tissue implants. If successful, Cellbricks is not just building better implants — it ... |
| 11.01.2025 | Aspect Biosystems: $115 Million (Series B) Secured To Develop Bioprinted Tissue Therapeutics | Aspect Biosystems – a biotechnology company advancing the development of bioprinted tissue therapeutics as a new category in regenerative medicine – announced that it has closed a $115 million Series B funding round. This funding round was ... |
| 09.01.2025 | Aspect Biosystems Raises US$115M in Series B Financing | Aspect Biosystems, a Vancouver, BC, Canada-based biotechnology company developing bioprinted tissue therapeutics for the regenerative medicine, raised US$115M in Series B funding. The round was led by Dimension, with participation from exis... |
| 12.04.2023 | Vancouver, B.C., tissue ‘bioprinting’ company inks $75M deal with Novo Nordisk for diabetes, obesity | An Aspect Biosystem scientist at work on a company bioprinter. (Aspect Photo) Vancouver, B.C.-based biotech company Aspect Biosystems inked a partnership worth potentially more than $2.6 billion with Danish biopharma giant Novo Nordisk to d... |
| 15.12.2022 | "I very rarely feel even close to being the smartest person in the room." — How (and why) to get a job at Aspect Biosystems | The How (and why) to get a job story series is supported by VanHack. Hire from VanHack’s 300K+ diverse tech talent pool, fast. Co-founder and chief scientific officer Sam Wadsworth (photo supplied). Sam Wadsworth had to move our call (to a ... |
| 22.11.2022 | Российский MedTech: старые проблемы и новые возможности | Российский рынок медицинских технологий на фоне мирового кажется карликом. Однако внимание со стороны бизнеса и государства в ближайшие годы предоставит ему широкие возможности для опережающего развития. 0 Обсудить 28 просмотров По данным S... |
| 22.09.2022 | Aspect Biosystems Appoints Three New Board Members Contacts | VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat disease, is pleased to announce the appointment of three new mem... |
| 10.08.2022 | Vancouver tech layoffs, talent, and hiring companies | As the innovation economy comes under pressure, a number of local tech companies have been forced to lay off employees. Here we’re sharing details on who has let go of staff, how to reach newly-available tech talent, and which companies are... |
| 09.04.2022 | Aspect Biosystems and JDRF to develop 3D bioprinted treatment for diabetes | Canadian 3D bioprinting firm Aspect Biosystems has unveiled a new partnership with the international diabetes research and advocacy organization JDRF. As part of the deal, JDRF has agreed to back Aspect Biosystems’ bid to create novel 3D bi... |
Show more